QLD4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (COMPLETED)4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (COMPLETED)

SA5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (COMPLETED)

NCT04064060

A Phase 3b, Open-label, Single-arm, Rollover Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials (U1111-1235-8123--ACE-536-LTFU-001)

NCT03959085

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (NCI-2019-02845--AALL1732)

NCT03486873

A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab (3475-587)

4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (COMPLETED)

NCT02960022

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study (9785-CL-0123)

2076 - Wahroonga - Sydney Adventist Hospital (COMPLETED)2485 - Tweed Heads - The Tweed Hospital (COMPLETED)2640 - Albury - Border Medical Oncology Research Unit (COMPLETED)

3000 - Melbourne - Peter MacCallum Cancer Centre (COMPLETED)3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (COMPLETED)3165 - East Bentleigh - Peter MacCallum Cancer Centre Moorabbin Campus (COMPLETED)

QLD4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (COMPLETED)

ACTRN12625000361404

A Phase 1, Multicentre, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FO-004 in Patients with advanced solid tumours.

ACTRN12625000309482

Accelerated Partial breast irradiation Using external beam Volumetric Modulated Arc Therapy (VMAT): a randomised non-inferiority trial of 30 Gy versus 26 Gy in five fractions investigating patient-reported outcomes. (PUMA)

ACTRN12624001230549

An assessment of cancer outcomes post cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal metastases with the use of a personalised aproach to choice of intraperitoneal chemotherapy agent individualised to a patient's specific tumour sensitivity in-vitro.

ACTRN12623001077651

A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination with Anticancer Treatments in Patients with Solid Malignancies - Module 2. (EMITT-1)

ACTRN12623000104651

Phase I Trial of the Safety and Efficacy of Deflexifol for Refractory or Recurrent Paediatric Central Nervous System (CNS) Tumours (DART)

ACTRN12622000083796

Medicinal Cannabis (MedCan 3) – a randomised, multicentre, double blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer (20))

ACTRN12622000037707

A prospective, multicentre, randomised, blinded, two-arm parallel trial of Medicinal Cannabis Products for symptom burden in children with advanced cancer (MINI)

ACTRN12621000227897

Not Applicable

Feasibility of Magnetic Resonance Imaging guided stereotactic reirradiation in patients who have previously received radiation for prostate cancer and have biochemical and local recurrence of cancer within the prostate (PRIUS-MR)

ACTRN12619000079145

A Phase I Study of Autologous CD19 Specific Chimeric Antigen Receptor T-cells for Therapy of Relapsed and Refractory B-cell Leukaemia and Lymphoma (The-AutoCAR19-Trial)

NCT04739670

A Single Arm Phase II Trial Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Early Relapsing Metastatic Triple Negative Breast Cancer (BELLA)

NCT03662126

A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT 232 in Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post-PV-MF), Or Post Essential Thrombocythemia MF (Post-ET-MF) Who Are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment (BOREAS)

PD-1/PD-L1	28%
PD-1	25%
VEGF	11%
oestrogen axis	11%
androgen axis	9%
AR	8%
PD-L1	7%
ER	7%
CYP17A1	6%
CDK4	5%
KRAS	5%
KRAS G12C	5%
CDK6	5%
TIGIT	5%
Nectin4	4%
VEGFA	4%
ERBB2	4%
PARP	4%
CD20	4%
CTLA4	3%
MET	3%
Trop2	3%
KLK2	3%
FR-alpha	3%
PARP1-selective	3%
cereblon	3%
EGFR	3%
ERBB3	3%
VEGFR2	2%
CDK2	2%
EZH2	2%
ERAP1	2%
BCMA	2%
BTK	2%
Bcl2	2%
LHRH	2%
WEE1	2%
AXL	1%
KIT	1%
RET	1%
ROS1	1%
VEGFR	1%
CDH17	1%
VEGFR1	1%
VEGFR3	1%
CDK4 selective	1%
FGFR3	1%
KAT6A	1%
mTOR	1%
mTORC1	1%
IDH1	1%
IDH1 R132	1%
GDF15	1%
CD38	1%
proteasome	1%
PI3K delta	1%
CLDN6	1%
CEACAM5	1%
FGFR2	1%
FGFR2b	1%
PRMT5	1%
ER alpha	1%
AKT	1%
AKT1	1%
SMO	1%
B7H3	1%
TTR	1%
BRAF	1%
CRAF	1%
FAK	1%
MEK	1%
RAF	1%
pan-RAF	1%
HPK1	1%
MUC18	1%
DNA-dependent protein kinase	1%
PSMA	1%
CD93	1%
gp100	1%
CS1	1%
CD44v9	1%
CLDN18.2	1%
CD19	1%
ROR1	1%
TP53	1%
TP53 Y220C	1%
CD22	1%
LAG3	1%
GnRH	1%
MDM2	1%

ARTICANZ - Beta (ver 0.91)

Search results

Filters